Dimethylargininase (DDAH) Inhibitor

PD 404182 is a potent and competitive inhibitor of human dimethylarginine dimethylaminohydrolase 1 (DDAH1), with an IC₅₀ of 9 μM. PD 404182 exhibits antiangiogenic and antiviral activity in vitro.

hDDAH-1-IN-1 (compound 8a) is a potent and selective non-amino acid catalytic site inhibitor of human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1), with a K_i of 18 μM. DDAH mediates ADMA metabolism, thereby regulating nitric oxide production in a variety of disease states.

Paris saponin VII (Standard) is the analytical standard of Paris saponin VII. This product is intended for research and analytical applications. Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia.

DDAH1-IN-3 is a DDAH1 inhibitor with a human IC₅₀ of 176 μM. DDAH1-IN-3 binds to the DDAH1 active site, forms binding interactions that remodel the binding pocket, and functionally inhibits the enzyme. DDAH1-IN-3 suppresses vasculogenic mimicry in triple-negative breast cancer cells. DDAH1-IN-3 can be used for the research of triple-negative breast cancer.